The Food and Drug Administration has recently authorized Novavax’s updated protein-based Covid vaccine for emergency use in individuals aged 12 and above. This approval paves the way for Novavax’s vaccine to compete with the current jabs offered by Pfizer and Moderna during the upcoming fall and winter seasons.
Novavax’s vaccine is specifically designed to target the highly contagious omicron subvariant JN.1, which has been spreading widely in the U.S. in recent months. Despite its low prevalence, accounting for only 0.2% of cases nationwide, the FDA has deemed it necessary to combat this particular strain of the virus.
Robust Cross-Reactivity and Availability
Novavax’s protein-based vaccines do not have the flexibility to be quickly updated to target new strains of the virus. However, the company has confirmed that its updated vaccine provides protection against various descendants of JN.1 that are currently dominant in the U.S. This includes strains like KP.2.3, KP.3, KP.3.1.1, and LB.1. CEO John Jacobs stated that the updated vaccine shows robust cross-reactivity against JN.1 lineage viruses. Novavax anticipates that its vaccine will be widely available in numerous locations across the U.S., including retail pharmacies, independent pharmacies, and regional grocers.
Following the announcement of the FDA’s authorization, shares of Novavax surged more than 8% on Friday. This decision comes shortly after the approval of new mRNA shots from Pfizer and Moderna targeting a different offshoot of JN.1 called KP.2. Last year, Novavax faced delays in receiving FDA authorization compared to its competitors. Public health officials view Novavax’s vaccine as a valuable alternative for individuals who are hesitant to receive mRNA shots from Pfizer and Moderna, which utilize a newer vaccine technology.
Final Thoughts
Novavax’s vaccine relies on protein-based technology, a tried-and-tested method used in routine vaccinations against diseases like hepatitis B and shingles. While the efficacy and uptake of Novavax’s vaccine in the upcoming fall and winter seasons remain uncertain, it offers a different approach compared to the mRNA vaccines available in the market. As the Covid situation continues to evolve, having a variety of vaccine options is crucial in providing individuals with choices that best suit their preferences and needs.